RxDoctor Payments Data

Weiss Moshref, PA

Surgical · Bakersfield, CANPI 1285605600

Payments from drug & device makers

$2,169in general payments, 2019–2025

Across 38 payments — averaging $57.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$1K
  • Biodelivery Sciences International, Inc.$525
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
  • Scilex Pharmaceuticals Inc.$82
  • Medtronic$77
  • Painteq LLC$44
  • plus $42 from 2 others

What the payments were for

  • Speaking & faculty fees$52524%
  • Food & beverage$1,62375%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,169 in reported general payments places this provider in the 80th percentile of 729 surgical providers in California.

See all surgical providers in California

Medicare billing

Part B allowed, 2024
$453,144
Medicare patients
967
Services billed
6,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,774$90,253
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen698$84,340
ZtlidoLidocaine79$46,044
Buprenorphine106$23,350
Lidocaine137$13,109
MovantikNaloxegol Oxalate31$12,122
Naloxone Hcl113$7,908
Gabapentin760$7,005
Diclofenac Sodium199$6,052
OxycontinOxycodone Hcl17$5,478
Fentanyl62$4,986
Morphine Sulfate ErMorphine Sulfate310$4,794
Pregabalin291$4,132
Cyclobenzaprine Hcl702$3,804
Oxycodone Hcl215$2,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$82$46,04479 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$25,299172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 surgical providers in California.

Other surgical in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →